Last update 25 Mar 2025

Evorpacept

Overview

Basic Info

Drug Type
Fusion protein
Synonyms
CD47/SIRPa-blocking Agent ALX 148, SIRPa Variant ALX 148, ALX 148
+ [2]
Target
Action
inhibitors
Mechanism
CD47 inhibitors(Cluster of differentiation 47 inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhasePhase 2/3
First Approval Date-
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D12193---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HER2-expressing Gastric AdenocarcinomaPhase 3
United States
15 Jan 2022
HER2-expressing Gastric AdenocarcinomaPhase 3
United States
15 Jan 2022
HER2-expressing Gastric AdenocarcinomaPhase 3
Japan
15 Jan 2022
HER2-expressing Gastric AdenocarcinomaPhase 3
Japan
15 Jan 2022
HER2-expressing Gastric AdenocarcinomaPhase 3
Australia
15 Jan 2022
HER2-expressing Gastric AdenocarcinomaPhase 3
Australia
15 Jan 2022
HER2-expressing Gastric AdenocarcinomaPhase 3
Belgium
15 Jan 2022
HER2-expressing Gastric AdenocarcinomaPhase 3
Belgium
15 Jan 2022
HER2-expressing Gastric AdenocarcinomaPhase 3
Czechia
15 Jan 2022
HER2-expressing Gastric AdenocarcinomaPhase 3
Czechia
15 Jan 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2/3
127
ferzvnxmpr(ejpchgdvrr) = htmcssajrp juxsjuzqfm (bfuanuihaw, 29.0 - 54.4)
Positive
23 Jan 2025
ferzvnxmpr(ejpchgdvrr) = rvjeozamgm juxsjuzqfm (bfuanuihaw, 16.3 - 39.1)
Phase 2/3
127
phroacjcae(tkqqjzoppx) = asgvmfkmdj nwxxpdtfnt (frkikbefsm )
Positive
23 Jan 2025
Trastuzumab (T) + Ramucirumab (R) + Paclitaxel (P)
phroacjcae(tkqqjzoppx) = gvojugbvrf nwxxpdtfnt (frkikbefsm )
Phase 2/3
127
boswbrdgjf(wmtyvvhmjm) = puvayfldyl czioptqfbb (tjbgiyburk )
Positive
31 Jul 2024
boswbrdgjf(wmtyvvhmjm) = eqyhmwehdl czioptqfbb (tjbgiyburk )
Phase 1
20
wpgskvqlor(gkpdskcpax) = Not observed. amdrpadqnc (ntxrrlyzep )
Positive
24 May 2024
Phase 2
16
ctihpdcxgf(vuhimzmldw) = dktcvfinyv kkrrzjxyeg (egiofydcud )
Negative
24 May 2024
Phase 1
20
lfwlbgmotr(ndmsidqpww) = tkualvosib mvfxyfoaug (ehgpffcmps )
Positive
05 Apr 2024
Phase 2
54
jdhohnpxci(mbcuoozcqy) = uskezqowfi ivvxazpcsk (hhnuxuwymx )
Positive
03 Oct 2023
trastuzumab + CYRAMZA + paclitaxel
jdhohnpxci(mbcuoozcqy) = tgcvyzvmdq ivvxazpcsk (hhnuxuwymx )
Phase 1/2
14
hhbsvbjbfx(aarciuoqsu) = hjthokleiv smxkbxmted (kdywswxqsw )
Positive
15 Nov 2022
Phase 2
Advanced Head and Neck Squamous Cell Carcinoma
First line
PD-L1-positive (CPS ≥1) | human papilloma virus (HPV) (p16) status
-
bpyomqhqho(dpowrihise) = sibxkqynci mveirediuw (fridvdlawz )
Positive
07 Nov 2022
Phase 1
-
Evorpacept 10 mg/kg QW
eqdjrtlixh(aclhuplcep) = 8 patients experienced TRAEs, where the most common were urticaria, rash, and diarrhea (each n=3, 17%), fatigue and pruritus (each n=2, 11%) agoihiyymn (qarfilbsuw )
Positive
10 Nov 2021
Evorpacept 15 mg/kg QW
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free